Ancora Heart

Archive

Ancora Heart Receives IDE Approval for CorCinch-HF Pivotal Study of the AccuCinch® Ventricular Restoration System

By

Ancora Heart Enrolls First Patient in The CORCINCH-HF Study

By

Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced enrollment of the first patient in the CORCINCH-HF pivotal trial.

Ancora Heart Secures $80 Million in Financing

By

Ancora Heart Appoints Mark Miles as Chief Commercial Officer

By

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restoration System

By

ANCORA HEART’S ACCUCINCH SYSTEM DEMONSTRATES SIGNIFICANT IMPROVEMENT IN QUALITY OF LIFE, CARDIAC STRUCTURE AND FUNCTION IN HEART FAILURE PATIENTS

By

Ancora Heart Inc. Reaches First Enrollment Milestone in CORCINCH-HF Heart Failure Pivotal Trial

By

Ancora Heart Inc. Reports Two-Year Results Demonstrating Sustained Benefits of AccuCinch® System in Heart Failure Patients

By

To Learn More

GET IN TOUCH